Vascular dementia is dementia caused by a series of strokes. Restricted blood flow due to strokes reduces oxygen and glucose delivery to the brain, causing cell injury and neurological deficits in the affected region. Subtypes of vascular dementia include subcortical vascular dementia, multi-infarct dementia, stroke-related dementia, and mixed dementia.
Cerebrovascular disease includes a variety of medical conditions that affect the blood vessels of the brain and the cerebral circulation. Arteries supplying oxygen and nutrients to the brain are often damaged or deformed in these disorders. The most common presentation of cerebrovascular disease is an ischemic stroke or mini-stroke and sometimes a hemorrhagic stroke. Hypertension is the most important contributing risk factor for stroke and cerebrovascular diseases as it can change the structure of blood vessels and result in atherosclerosis. Atherosclerosis narrows blood vessels in the brain, resulting in decreased cerebral perfusion. Other risk factors that contribute to stroke include smoking and diabetes. Narrowed cerebral arteries can lead to ischemic stroke, but continually elevated blood pressure can also cause tearing of vessels, leading to a hemorrhagic stroke.
Stroke is a medical condition in which poor blood flow to a part of the brain causes cell death. There are two main types of stroke: ischemic, due to lack of blood flow, and hemorrhagic, due to bleeding. Both cause parts of the brain to stop functioning properly.
Carotid endarterectomy is a surgical procedure used to reduce the risk of stroke from carotid artery stenosis. In endarterectomy, the surgeon opens the artery and removes the plaque. The plaque forms and thickens the inner layer of the artery, or intima, hence the name of the procedure which simply means removal of part of the internal layers of the artery.
Sneddon's syndrome is a form of arteriopathy characterized by several symptoms, including:
Tinzaparin is an antithrombotic drug in the heparin group. It is a low molecular weight heparin (LMWH) marketed as Innohep worldwide. It has been approved by the U.S. Food and Drug Administration (FDA) for once daily treatment and prophylaxis of deep vein thrombosis (DVT) and pulmonary embolism (PE).
NeuroAiD is a herbal supplement proposed to support functional recovery after strokes. There were two formulations of NeuroAiD: MLC601 (NeuroAiDTM) was first developed. Since 2018 MLC601 formulation is no longer on the market, and has been replaced by MLC901 (NeuroAiDTMII), a simplified formulation containing only 9 botanical ingredients. It can be administered orally or through a feeding tube.
Technetium (99mTc) exametazime is a radiopharmaceutical sold under the trade name Ceretec, and is used by nuclear medicine physicians for the detection of altered regional cerebral perfusion in stroke and other cerebrovascular diseases. It can also be used for the labelling of leukocytes to localise intra-abdominal infections and inflammatory bowel disease. Exametazime is sometimes referred to as hexamethylpropylene amine oxime or HMPAO, although correct chemical names are:
Louis R. Caplan is an American physician who is a senior member of the Division of Cerebrovascular Disease at Beth Israel Deaconess Medical Center, Boston. He is a Professor of Neurology at Harvard Medical School, Boston, and the founder of the Harvard Stroke Registry at Beth Israel Deaconess Medical Center. Caplan is the author or editor of 51 books and more than 700 articles in medical journals.
Recent epidemiologic studies confirm that stroke is the most frequent cause of death in the People's Republic of China, with an incidence more than fivefold that of myocardial infarction. Intracerebral hemorrhage causes about one third of all strokes, nearly three times the frequency in North American stroke registries. A marked regional variation in stroke incidence exists, with a threefold higher stroke incidence in northern than in southern Chinese cities, suggesting important environmental or dietary influences. Stroke treatment often involves a combination of modern and traditional herbal medicine; the latter may modify platelet aggregation and blood viscosity. Stroke, particularly intracerebral hemorrhage, is the most frequent and important vascular disorder in China.
The Center for Cerebrovascular Research at the University of California, San Francisco is a collective of faculty and staff investigating matters related to cerebral circulation, particularly cerebrovascular disease resulting from narrowing of major blood vessels in the brain and vascular malformation of the brain. While research offices are located on Parnassus campus, San Francisco General Hospital hosts the center's laboratories and facilities. The center coordinates with additional faculty in various fields of neuroscience and vascular biology. Sponsors include the National Institute of Neurological Disorders and Stroke and the UCSF departments of Anesthesia, Neurological Surgery and Neurology.
Pankaj Sharma is a British professor of Clinical Neurology at Royal Holloway College, University of London, and consultant neurologist at Imperial College London. He is director of the Institute of Cardiovascular Research at Royal Holloway (ICR2UL), and formerly head of the Imperial College Cerebrovascular Research Unit (ICCRU) at Imperial College London. His main interest is in identifying genes for stroke, particularly in those of South Asian heritage.
Piclozotan (SUN-N4057) is a selective 5-HT1A receptor partial agonist, which has neuroprotective effects in animal studies. It has been through early clinical trials in humans for treatment of acute stroke, but results have not yet been announced.
Barrow Neurological Institute is the world's largest neurological disease treatment and research institution, and is consistently ranked as one of the best neurosurgical training centers in the United States. Founded in 1962, the main campus is located at 350 W. Thomas Road in Phoenix, Arizona.
In medical terms, an insult is the cause of some kind of physical or mental injury. For example, a burn on the skin may be the result of a thermal, chemical, radioactive, or electrical event. Likewise, sepsis and trauma are examples of foreign insults, and encephalitis, multiple sclerosis, and brain tumors are examples of insults to the brain. Clinicians may use the term cerebrovascular insult (CVI) as a synonym for a stroke.
Fanapanel, also known as MPQX, is a quinoxalinedione derivative drug which acts as a competitive antagonist of the AMPA receptor. It was under development by Schering AG for the treatment of cerebral ischemia associated with stroke and trauma, but clinical trials were halted for safety reasons related to possible glial cell toxicity and due to intolerable side effects such as excessive sedation, reduction in consciousness, and transient neurological deterioration. The drug was also observed to produce visual alteration and impairment, including blurred vision, strongly impaired color perception, and reduced visual acuity and dark vision, side effects thought to be caused by blockade of AMPA receptors in the retina.
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease is a peer-reviewed open access scientific journal and an official journal of the American Heart Association. Since 2015, it is also published with John Wiley & Sons. It was established in 2012 and the editor-in-chief is Bruce Ovbiagele.
Cerebrovascular Diseases is a peer-reviewed medical journal covering the study of cerebrovascular diseases. It was established in 1991 by Michael G. Hennerici and Julien Bogousslavsky, and is published eight times per year by Karger Publishers. Hennerici is the journal's editor-in-chief. According to the Journal Citation Reports, the journal has a 2016 impact factor of 2.974.
Cerebrovascular diseases in Australia are a major health issue. Cerebrovascular disease is a significant challenge to Australia due to it being a prominent cause of death in Australians and the difficulties it poses for carers and the health system in addition to individuals with cerebrovascular disease. Stroke is the deadliest cerebrovascular disease in Australia accounting for 84.24% of all deaths caused by cerebrovascular diseases. The death rate of cerebrovascular diseases is decreasing, with cerebrovascular disease in 2008-2018 falling from the third to fourth leading cause of death for men and second to third leading cause of death for women during this time period. In 2015, stroke was the tenth leading cause of burden of disease, accounting for 2.7% of the overall burden. This cause of disease burden has decreased from 2003 to 2015 with stroke falling from the second leading cause of disease burden to the tenth during this time period. Aboriginal and Torres Strait Islander people and people from low-socioeconomic areas experience higher rates of prevalence and mortality from stroke than non-Indigenous Australians.
